Oil Holds Drop as Trump Threatens India for Taking Russian Crude
West Texas Intermediate held above $66 a barrel after shedding more than 5% over the prior three sessions, while Brent settled below $69. Trump said he would be ' substantially raising ' the tariff on Indian exports to the US over the nation's purchases of Russian oil as part of a bid to force Moscow to agree a truce in Ukraine. New Delhi slammed the move as unjustified.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
India and the Philippines announce partnership to strengthen trade, defense and maritime ties
India Philippines NEW DELHI (AP) — India and the Philippines announced an upgraded strategic partnership Tuesday that they said will deepen trade, defense and maritime cooperation between the two nations. The countries announced the agreement after bilateral talks in New Delhi between Indian Prime Minister Narendra Modi and visiting Philippine President Ferdinand Marcos. India's foreign ministry spokesman, Randhir Jaiswal, said the sides also agreed to expand partnerships in space, tourism, culture and digital technologies. After the talks, Modi said India and the Philippines were 'committed to peace, security, prosperity and a rules-based order in the Indo-Pacific region.' Marcos said the strategic partnership 'will doubtless resonate beyond the confines of our bilateral relationship.' 'We want to work with you for a free and open Indo-Pacific," he told Modi. Marcos arrived in India on Monday for a five-day visit as the countries deepen their defense ties. They staged joint naval exercises in the disputed South China Sea for the first time on Sunday, a high-profile military deployment that antagonized China. India also has supplied its BrahMos supersonic cruise missile systems to Philippines. Solve the daily Crossword
Yahoo
24 minutes ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Coinbase premium just dropped a huge signal for Bitcoin's price to hit $130,000
US investors are quietly piling into Bitcoin after a wobble that saw its price decline 4% in the last week amid a $9 billion selloff and late-month geopolitical jitters. The bubbling buying spree is visible in the Coinbase Bitcoin premium gap on CryptoQuant, a market data platform. The metric tracks the difference in the Bitcoin price on Coinbase Pro and other exchanges, including Binance. It has flipped positive, signalling that US demand is rebounding, further fuelling analysts' bullishness on Bitcoin's long-term price prospects. 'Bitcoin to trade between $130,000 and $150,000 by year-end, assuming continued [exchange-traded fund] inflows and a stable macro environment, [but] much will hinge on upcoming Federal Reserve decisions, particularly the anticipated rate cut in September,' analysts at TeraHash, a Bitcoin yield protocol, told DL News. An interest rate slash by the Federal Reserve is seen as rocket fuel for Bitcoin because lower interest rate environments favour assets like crypto and stocks. And traders are already pricing in an 88% chance of a September rate cut, according to the CME's FedWatch tool. James Butterfill, head of research at CoinShares, a crypto investment firm, said he expects the Federal Reserve to pivot sharply dovish, a policy shift that favours growth over inflation control, usually by reducing interest rates for cheaper borrowing. 'The Fed is on the back foot and overly concerned with transitory inflation issues and is likely to do a knee-jerk rate cut; it's debatable as to whether this will be September or later, though,' Butterfill said. To be sure, some analysts say Bitcoin has lost some momentum in the short term following its recent price slump. Analysts at Bitfinex, a crypto exchange, say they expect Bitcoin to consolidate between $114,000 and $116,000 unless something triggers new market moves. Bitcoin traded just above $114,000 on Tuesday, down 7% from its all-time high of $122,838 achieved on July 14. Crypto market movers Bitcoin has gained 0.4% over the past 24 hours and is trading at $114,747. Ethereum is up 3.1% in the same period to $3,671. What we're reading Aave's $4.7bn Ethena exposure risks setting off 'liquidity crunch,' adviser says — DL News CurveDAO Member Proposes Cutting L2 Deployments — Unchained Can PumpFun be dethroned? — Milk Road Crypto Donors Sent $45 Million to Trump's Super PAC: Report — Unchained Why Mode Network's investor deposits dropped 99% in one year — DL News Osato Avan-Nomayo is our Nigeria-based DeFi correspondent. He covers DeFi and tech. Got a tip? Please contact him at osato@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
